Evergreen. CeMines(TM) Inc., a privately
held company founded in 2000 that employs
genomics and
proteomics information
as building blocks for the development of early-stage
diagnostics of diseases
and therapeutics targeted for
gene regulation, today announced that the
company has created a new business unit: the
CeMines BioSystems Division.
Roger Attick, president & chief executive officer of CeMines, stated: "This
newest business unit is a catalyst for bifurcated growth. We have created the
infrastructure necessary to enable CeMines to immediately accelerate the
growth of sales from our existing product line of Research Tools, including
antibodies, cDNA and mRNA, and at the same time commence with our market
introduction of a new family of products targeted at establishing CeMines as a
premier brand in drug discovery and other markets."
Creation of the new BioSystems Division comes on the heels of an
announcement in June that CeMines has expanded its Diagnostics & Therapeutics
Research Division and relocated it from Los Angeles to La Jolla, Calif. The
new 9,000-square-foot, state-of-the-art facility in La Jolla is a substantial
increase in R&D space-expansion made necessary by the Company's aggressive
growth expectations to support preparation for
clinical trials in the U.S. and
Europe, and to introduce new products.
"Looking back," said Attick, "our Research Tools group enabled CeMines to
develop critical revenue channels during the early stages of our R&D in
molecular diagnostics and therapeutics. Simply stated, we seized these
opportunities for revenues by selling Research Tools into the academia and
research markets. The early revenues helped subsidize a good portion of
operating expense during the critical stages of our development.
"Times are changing in
Life Sciences. It is clear to us that it is now
time for CeMines to become a more aggressive competitor. The BioSystems
Division is developing product kits, integrated with applications, that will
enable our customers-researchers and
drug development companies-to advance the
progress of their own product development and research," said Roger Attick,
who also is acting general manager of the new division. "Recent R&D advances
at CeMines can now be further leveraged, thereby enabling CeMines to begin a
new phase of market growth. This is extremely important, especially
considering that CeMines is preparing to usher-in our first diagnostic
products for large-scale clinical trials here in the United States," stated
Attick.